Literature DB >> 35663253

Immune Checkpoint Inhibitors in Gastrointestinal Malignancies: What Is the Path Forward?

Vaia Florou1, Ignacio Garrido-Laguna1.   

Abstract

Entities:  

Year:  2020        PMID: 35663253      PMCID: PMC9165577          DOI: 10.36401/JIPO-20-X5

Source DB:  PubMed          Journal:  J Immunother Precis Oncol        ISSN: 2590-017X


× No keyword cloud information.
  10 in total

1.  Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study.

Authors:  Michael J Overman; Ray McDermott; Joseph L Leach; Sara Lonardi; Heinz-Josef Lenz; Michael A Morse; Jayesh Desai; Andrew Hill; Michael Axelson; Rebecca A Moss; Monica V Goldberg; Z Alexander Cao; Jean-Marie Ledeine; Gregory A Maglinte; Scott Kopetz; Thierry André
Journal:  Lancet Oncol       Date:  2017-07-19       Impact factor: 41.316

2.  Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.

Authors:  Dung T Le; Jennifer N Durham; Kellie N Smith; Hao Wang; Bjarne R Bartlett; Laveet K Aulakh; Steve Lu; Holly Kemberling; Cara Wilt; Brandon S Luber; Fay Wong; Nilofer S Azad; Agnieszka A Rucki; Dan Laheru; Ross Donehower; Atif Zaheer; George A Fisher; Todd S Crocenzi; James J Lee; Tim F Greten; Austin G Duffy; Kristen K Ciombor; Aleksandra D Eyring; Bao H Lam; Andrew Joe; S Peter Kang; Matthias Holdhoff; Ludmila Danilova; Leslie Cope; Christian Meyer; Shibin Zhou; Richard M Goldberg; Deborah K Armstrong; Katherine M Bever; Amanda N Fader; Janis Taube; Franck Housseau; David Spetzler; Nianqing Xiao; Drew M Pardoll; Nickolas Papadopoulos; Kenneth W Kinzler; James R Eshleman; Bert Vogelstein; Robert A Anders; Luis A Diaz
Journal:  Science       Date:  2017-06-08       Impact factor: 47.728

3.  Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study.

Authors:  Aurelien Marabelle; Dung T Le; Paolo A Ascierto; Anna Maria Di Giacomo; Ana De Jesus-Acosta; Jean-Pierre Delord; Ravit Geva; Maya Gottfried; Nicolas Penel; Aaron R Hansen; Sarina A Piha-Paul; Toshihiko Doi; Bo Gao; Hyun Cheol Chung; Jose Lopez-Martin; Yung-Jue Bang; Ronnie Shapira Frommer; Manisha Shah; Razi Ghori; Andrew K Joe; Scott K Pruitt; Luis A Diaz
Journal:  J Clin Oncol       Date:  2019-11-04       Impact factor: 44.544

Review 4.  The Immunoscore: Colon Cancer and Beyond.

Authors:  Helen K Angell; Daniela Bruni; J Carl Barrett; Ronald Herbst; Jérôme Galon
Journal:  Clin Cancer Res       Date:  2019-08-14       Impact factor: 12.531

5.  Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer.

Authors:  Michael J Overman; Sara Lonardi; Ka Yeung Mark Wong; Heinz-Josef Lenz; Fabio Gelsomino; Massimo Aglietta; Michael A Morse; Eric Van Cutsem; Ray McDermott; Andrew Hill; Michael B Sawyer; Alain Hendlisz; Bart Neyns; Magali Svrcek; Rebecca A Moss; Jean-Marie Ledeine; Z Alexander Cao; Shital Kamble; Scott Kopetz; Thierry André
Journal:  J Clin Oncol       Date:  2018-01-20       Impact factor: 44.544

6.  Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study.

Authors:  Van K Morris; Mohamed E Salem; Halla Nimeiri; Syma Iqbal; Preet Singh; Kristen Ciombor; Blase Polite; Dustin Deming; Emily Chan; James L Wade; Lianchun Xiao; Tanios Bekaii-Saab; Luis Vence; Jorge Blando; Armeen Mahvash; Wai Chin Foo; Chimela Ohaji; Manolo Pasia; Gail Bland; Aki Ohinata; Jane Rogers; Amir Mehdizadeh; Kimberly Banks; Richard Lanman; Robert A Wolff; Howard Streicher; James Allison; Padmanee Sharma; Cathy Eng
Journal:  Lancet Oncol       Date:  2017-02-18       Impact factor: 41.316

7.  Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal.

Authors:  P A Ott; S A Piha-Paul; P Munster; M J Pishvaian; E M J van Brummelen; R B Cohen; C Gomez-Roca; S Ejadi; M Stein; E Chan; M Simonelli; A Morosky; S Saraf; K Emancipator; M Koshiji; J Bennouna
Journal:  Ann Oncol       Date:  2017-05-01       Impact factor: 32.976

8.  Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: KEYNOTE-164.

Authors:  Dung T Le; Tae Won Kim; Eric Van Cutsem; Ravit Geva; Dirk Jäger; Hiroki Hara; Matthew Burge; Bert O'Neil; Petr Kavan; Takayuki Yoshino; Rosine Guimbaud; Hiroya Taniguchi; Elena Elez; Salah-Eddin Al-Batran; Patrick M Boland; Todd Crocenzi; Chloe E Atreya; Yi Cui; Tong Dai; Patricia Marinello; Luis A Diaz; Thierry André
Journal:  J Clin Oncol       Date:  2019-11-14       Impact factor: 44.544

9.  Prospective Genotyping of Hepatocellular Carcinoma: Clinical Implications of Next-Generation Sequencing for Matching Patients to Targeted and Immune Therapies.

Authors:  Nikolaus Schultz; Ghassan K Abou-Alfa; James J Harding; Subhiksha Nandakumar; Joshua Armenia; Danny N Khalil; Melanie Albano; Michele Ly; Jinru Shia; Jaclyn F Hechtman; Ritika Kundra; Imane El Dika; Richard K Do; Yichao Sun; T Peter Kingham; Michael I D'Angelica; Michael F Berger; David M Hyman; William Jarnagin; David S Klimstra; Yelena Y Janjigian; David B Solit
Journal:  Clin Cancer Res       Date:  2018-10-29       Impact factor: 12.531

Review 10.  Precision medicine becomes reality-tumor type-agnostic therapy.

Authors:  Li Yan; Wei Zhang
Journal:  Cancer Commun (Lond)       Date:  2018-03-31
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.